Cellect Biotechnology Ltd. (APOP) EPS Estimated At $-0.30 as of June, 4

May 17, 2018 - By Alice Reed

Cellect Biotechnology Ltd. (NASDAQ:APOP)’s quarterly earnings will be announced on June, 4., RTT reports. The earnings per share diference is $0.26 or 650.00 % down from last years number. Previous year: $-0.04; Analysts forcast: $-0.30. Wall Street forecasts 87.50 % negative EPS growth as of June, 4. APOP is reaching $7.13 during the last trading session, after increased 0.28%.Currently Cellect Biotechnology Ltd. is downtrending after 42.02% change in last May 17, 2017. APOP has 17,074 shares volume. APOP underperformed by 53.57% the S&P 500.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel.The firm is valued at $46.41 million. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.Currently it has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.